Lymphoma Treatment in Lu Daopei Hematology Hospital

Lu Daopei Hematology Hospital in Beijing specializes in advanced lymphoma treatment. Options include Pre-CAR-T preparation for around $25,000, full CAR-T cell therapy at $60,000-$68,000, and combined CAR-T with radiotherapy for approximately $100,000. As a dedicated hematology center, it provides international patient services, director-level coordination, and 45 days of inpatient care within treatment packages.

Comprehensive Lymphoma Diagnostics

The hospital offers a full diagnostic workup for lymphoma. Essential tests like PET-CT scans and bone marrow biopsies are included in the CAR-T therapy package. This provides a clear picture of the disease before treatment begins.

Available Treatment Options

Lu Daopei provides a complete pathway for lymphoma care. This starts with preparation and extends to complex cellular therapies.

• Pre-CAR-T Preparation & Bridging Therapy: This stage may cost between $25,000 and $30,000. It includes bridging chemotherapy to reduce tumor load. Biomarker confirmation (CD19/CD22) is also performed.
• CAR-T Cell Therapy: The core immunotherapy typically runs $60,000 to $68,000. It uses personalized, genetically modified T-cells to target lymphoma. The package includes the cell product, infusion, a 45-day hospital stay, pre-op tests, hotel accommodation, and airport transfers.
• Combined CAR-T with Local Radiotherapy: This comprehensive approach may cost around $100,000. It adds targeted radiotherapy to the CAR-T protocol for enhanced tumor control.

Patient Services and Support

Dr. Bo Chen, PhD, serves as the International Patient Services Director. He facilitates coordination for overseas patients. The hospital provides full support including visa assistance, airport transfers, and translation services. It is a specialized hematology center with a focus on personalized treatment plans. The facility holds a 5-star rating based on patient reviews.

Patients seeking a specialized center for lymphoma can consult with the clinic's international team to explore these treatment pathways.